

Press release

ABIONYX Pharma, winner of the France 2030 Plan's "i-Démo" call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide



- **The « i-Démo » call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government, enables ABIONYX Pharma to revolutionize the treatment of Sepsis through its synthetic biomedicine CER-001, imitating apoA-I,**
- **The apoA-I is a circulating protein very important in the human body due to its effects on reducing severe inflammation and protecting tissues and organs,**
- **ABIONYX Pharma, the only company in the world that synthesizes and industrially produces this pure apoA-I, which is more stable and more functional than the natural protein, is one of the 20 biotherapy projects selected, benefiting from €8.7 million of which 26% in subsidies.**

Toulouse, FRANCE, Westlake CA, UNITED-STATES, February 20th, 2025, 7:30 am CET – ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world's only natural recombinant apoA-I, announces today that its clinical development in sepsis has been selected as part of the "i-Démo" call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government.

After 6 months of examining ABIONYX Pharma's CER-001 Sepsis project, a panel of experts was able to validate and objectify the quality of the project in its scientific, technological and

clinical aspects.

The CER-001 Sepsis project represents a strategic cornerstone for ABIONYX Pharma, leveraging its unique expertise to use the only recombinant apoA-I protein in the treatment of the most severe inflammation in the human body.

Sepsis, also known as generalized infection or septic shock in its severe forms, is a global plague that affects more than **49 million people each year**, causing nearly **11 million deaths**, or about **1 in 5 deaths worldwide**. It is an uncontrolled immune response to an infection, which leads to multi-organ failure and high mortality, particularly in intensive care patients. Despite advances in critical care, there is currently **no specific and targeted treatment for sepsis**, and current therapeutic options are mainly limited to antibiotics, supportive care and symptomatic management.

Recombinant apoA-I (CER-001) represents an exceptional therapeutic opportunity in this field. Thanks to its anti-inflammatory, antioxidant and immune-modulating properties, it acts directly on the underlying pathophysiological mechanisms of sepsis, by neutralizing endotoxins, reducing cytokine storms and protecting vital organs from damage. This innovative approach offers hope of transforming the management of sepsis by proposing a treatment that is effective, targeted and capable of significantly reducing mortality and long-term complications.

The ABIONYX Pharma Sepsis project currently operates on two strategic fronts:

1. An integrated biomedicine approach: ABIONYX Pharma develops a combined bioproduction/biotherapy approach secured by proprietary patents until 2042 along the entire chain.
2. An innovative clinical strategy: circulating apoA-I collapses in situations of severe inflammation. Supplementation with recombinant human apoA-I in these critical situations enables to treat all types of patients, even immuno-depressed patients. Based on the very positive Phase 2a clinical results, the Phase 2b/3 study between the United States and Europe aims to confirm a significant reduction in mortality.

ABIONYX Pharma is the world leader in recombinant apoA-I, the result of 20 years of expertise and innovation in lipid metabolism, bioproduction and the clinical development of this unique bioproduct. With its exceptional know-how, ABIONYX Pharma demonstrated the safety, efficacy and therapeutic potential of apoA-I in critical indications, particularly in LCAT deficiency, a rare disease, and is now exploring the most severe inflammatory diseases such as cytokine storms and severe inflammation in ophthalmology and neurology.

About ABIONYX Pharma

ABIONYX Pharma is a next-generation biotech company that aims to contribute to health through innovative therapies in indications where there is no effective or existing treatment, even the rarest ones. Thanks to its partners in research, medicine, biopharmaceuticals and shareholding, the company innovates on a daily basis to propose drugs for the treatment of renal and ophthalmological diseases, or new apoA-I vectors used for targeted drug delivery.

Contacts:

NewCap

Investor relations
Nicolas Fossiez
Louis-Victor Delouvrier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

NewCap

Media relations
Arthur Rouillé
abionyx@newcap.eu
+33 (0)1 44 71 00 15

About the France 2030 Investment Plan

- Embodies a dual ambition: to transform key sectors of our economy (healthcare, energy, automotive, aerospace, and space) through technological innovation, and to position France not only as a player but as a leader in the world of tomorrow. From fundamental research to the emergence of an idea to the production of a new product or service, France 2030 supports the entire life cycle of innovation until its industrialization.
- Unprecedented in scale: €54 billion will be invested to ensure that our companies, universities, and research organizations fully succeed in their transitions in these strategic sectors. The aim is to enable them to competitively address the ecological challenges and attractiveness of the emerging world, and to foster the emergence of future leaders in our fields of excellence. France 2030 is defined by two transversal objectives: to allocate 50% of its expenditure to decarbonizing the economy, and 50% to emerging actors, promoting innovation without adverse effects on the environment (in line with the Do No Significant Harm principle).
- Implemented collectively: France 2030 is designed and deployed in consultation with economic, academic, local, and European stakeholders to determine its strategic orientations and flagship actions. Project sponsors are invited to submit their applications through open, rigorous, and selective procedures to benefit from state support.
- Led by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the Agency for Ecological Transition (ADEME), the National Research Agency (ANR), Bpifrance, and the Caisse des Dépôts et Consignations (CDC).
More information at: www.info.gouv.fr/france-2030 | [@SGPI_avenir](https://twitter.com/SGPI_avenir)

About Bpifrance

Bpifrance finances companies at every stage of their development – in credit, guarantees, and equity. It supports them in their innovation projects and international endeavors. Bpifrance now also ensures their export activity through a wide range of products. Advice, university support, networking, and acceleration programs for startups, SMEs, and mid-sized companies are also part of the offerings provided to entrepreneurs. With Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, unique, and effective interlocutor to help them face their challenges.

www.bpifrance.fr | www.presse.bpifrance.fr/ | [@Bpifrance](https://twitter.com/Bpifrance) | [@Bpifrance](https://twitter.com/Bpifrance)